Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Cervical Cancer Clinical Trials

A listing of Cervical Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (11) clinical trials

A clinical trial seeking patients for a research study of Aminolaevulinic acid, Placebo

This trial will study the effectiveness of photodynamic therapy with aminolaevulinic acid for the treatment of patients with HPV+ low grade cervical intraepithelial neoplasia (LSIL;CIN1).


A clinical trial sponsored by M.D. Anderson Cancer Center for a research study for the treatment of Cervical Cancer

Stage IA2 or IB1 cervical cancer is currently treated by a radical hysterectomy (removal of the uterus, cervix, and the parametrium) or radical trachelectomy (removal of the cervix and the parametrium). The parametrium is the tissue next to the uterus and cervix that holds these organs in place. Pelvic lymph ...


A clinical trial sponsored by Agenus Inc. for a research study of AGEN2034

This is a Phase 1, open-label, 3 + 3 dose-escalation trial in subjects with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum doublet.


A Phase 2 clinical study for patients with Cervical Intraepithelial Neoplasia, Cervical Cancer

LN-145 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI, for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma. The cell transfer therapy used in this study involves patients receiving a NMA lymphocyte depleting preparative regimen, followed ...


Patients are needed to participate in a clinical research study of Adavosertib, Cisplatin

PRIMARY OBJECTIVES: I. To determine the recommended phase II dose (RP2D) and safety profile of WEE1 inhibitor AZD1775 (AZD1775) in combination with radiotherapy and concurrent cisplatin in patients with gynecological cancers. SECONDARY OBJECTIVES: I. To determine the acute and late toxicity of AZD1775 when administered to patients with gynecological cancer ...


Patients are needed to participate in a clinical research study to evaluate Recurrent Glioma, Thyroid Adenoma, Colorectal Cancer, Lung Neoplasm, Uterine Corpus Cancer, Ovarian Cancer, Recurrent Thyroid Gland Carcinoma, Recurrent Breast Carcinoma, Recurrent Colon Carcinoma, Recurrent Liver Carcinoma, Pancreatic Cancer, Malignant neoplasm of kidney, Ductal Carcinoma In Situ, Recurrent Pancreatic Carcinoma, melanoma, Malignant neoplasm of prostate, bladder cancer, Advanced Malignant Solid Neoplasm, Recurrent Lymphoma, Renal Cell Carcinoma, Uterine Cancer, Endometrial Carcinoma, Malignant neoplasm of colon, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Refractory Lymphoma, Lymphoma, Breast Cancer, Cervical Cancer, Skin Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Head and Neck Carcinoma, Esophageal Carcinoma, Refractory Plasma Cell Myeloma, Recurrent Cervical Carcinoma, Multiple Myeloma, Recurrent Lung Carcinoma, Head and Neck Carcinoma, Recurrent Skin Carcinoma, Recurrent Bladder Carcinoma, Recurrent Malignant Solid Neoplasm, Rectal Cancer, Recurrent Plasma Cell Myeloma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Glioma, Recurrent Rectal Carcinoma, Cervical Intraepithelial Neoplasia, Liver and Intrahepatic Bile Duct Carcinoma, Gastric Carcinoma, Recurrent Colorectal Carcinoma, skin cancer, Refractory Malignant Solid Neoplasm

PRIMARY OBJECTIVES: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced ...


A clinical research study of Triapine, Cisplatin

PRIMARY OBJECTIVES: I. To evaluate the efficacy of the experimental regimen of triapine (3AP), cisplatin, and radiation to increase progression-free survival relative to the standard/control regimen of cisplatin and radiation in women with uterine cervix and vaginal cancer. SECONDARY OBJECTIVES: I. To determine the post-therapy 3-month fludeoxyglucose F-18 (18F-FDG) positron ...


A clinical research study of cyclophosphamide, pembrolizumab, aldesleukin, fludarabine for the treatment of Vulvar Diseases, Carcinoma in Situ, Papillomavirus Infections, Malignant neoplasm of vulva, Cervical Intraepithelial Neoplasia

Background Metastatic or refractory/recurrent human papillomavirus (HPV)-16+ cancers (cervical, vulvar, vaginal, penile, anal, and oropharyngeal cancers) are incurable and poorly palliated by standard therapies. HPV-16+ cancers constitutively express the HPV-16 E7 oncoprotein, which is absent from healthy human tissues. Administration of T cell receptor (TCR) gene engineered T cells can ...


A Phase 2 clinical study for patients with Thyroid Adenoma, Testicular Non-Seminomatous Germ Cell Tumor, Malignant Odontogenic Neoplasm, Primary Peritoneal High Grade Serous Adenocarcinoma, Bladder Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Gastric Squamous Cell Carcinoma, Transitional cell carcinoma, Urethral Adenocarcinoma, Mucinous Adenocarcinoma, Nasal Cavity Adenocarcinoma, Paranasal Sinus Adenocarcinoma, Chordoma, Appendix Mucinous Adenocarcinoma, Anal Canal Neuroendocrine Carcinoma, Lung Carcinoid Tumor, Metaplastic Breast Carcinoma, Adrenocortical carcinoma, Mucinous cystadenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Major Salivary Gland Carcinoma, Extrahepatic Bile Duct Carcinoma, Adenoid Cystic Carcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Nasopharyngeal Papillary Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ureter Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma, Placental site trophoblastic tumor, Vulvar Adenocarcinoma, Parathyroid Adenoma, Ovarian Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Rare Diseases, Paraganglioma, Pheochromocytoma, Endometrial Transitional Cell Carcinoma, Seminoma, Undifferentiated Gastric Carcinoma, Vaginal Adenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Acinar Cell Carcinoma, Pseudomyxoma Peritonei, Mesodermal mixed tumor, Islet cell carcinoma, Serous cystadenocarcinoma, Minimally Invasive Lung Adenocarcinoma, Fallopian Tube Adenocarcinoma, Ureter Adenocarcinoma, Nasopharyngeal Cancer, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Spindle Cell Neoplasm, Colorectal Squamous Cell Carcinoma, Endometrioid carcinoma, Cervical Adenocarcinoma, Malignant Testicular Sex Cord-Stromal Tumor, Esophageal Undifferentiated Carcinoma, Paranasal Sinus Cancer, Placental Choriocarcinoma, Pituitary Adenoma, Aggressive fibromatosis, Fibromyxoid Tumor, Teratoma With Malignant Transformation, Vulvar Carcinoma, Ovarian Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Penis, Urethral Squamous Cell Carcinoma, Fallopian Tube Transitional Cell Carcinoma, Cholangiocarcinoma, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Nasopharyngeal Undifferentiated Carcinoma, Giant cell carcinoma, Dermoid Cyst, Gastric Neuroendocrine Carcinoma, Tracheal Carcinoma, Oral Cavity Carcinoma, Nerve Sheath Tumors, Lung Sarcomatoid Carcinoma, Nasal Cavity Carcinoma, Neoplasms, Unknown Primary, Anal Canal Undifferentiated Carcinoma, gastrointestinal stromal tumor, Oropharyngeal Undifferentiated Carcinoma

PRIMARY OBJECTIVES: I. To evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy. SECONDARY OBJECTIVES: I. To evaluate toxicities in each cohort. II. To estimate overall survival (OS), progression-free ...


A clinical trial to evaluate treatments for patients with Cervical Cancer Stage IVA, Vaginal Cancer Stage III, Cervical Cancer Stage IVB, Vulvar Cancer, Stage III, Ovarian Cancer Stage III, Endometrial Cancer Stage IV, Vulvar Cancer, Stage IV, Vaginal Cancer Stage IVB, Vaginal Cancer Stage IVA, Ovarian Cancer Stage IV, Cervical Cancer Stage IIIB, Endometrial Cancer Stage III, Breast Cancer Stage IV

Background: When faced with the challenges of advanced cancer, women must advocate (or stand up) for their needs and priorities. However, there are no interventions to promote self-advocacy among female patients with advanced cancer. Preliminary work has developed a theoretically-based, psychometrically-strong measure of self-advocacy (the Female Self-Advocacy in Cancer Survivorship ...

Phase N/A